Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

An International Multicentric Observational Study on the Use of Ruxolitinib in Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea: Results from Interim Analysis

Peter AW te Boekhorst, MD PhD, Alexandre Theocharides, MD, Heinz Gisslinger, MD, Timothy Devos, MD, Eric Lippert, MD PhD, Damianos Sotiropoulos, MD, Miklos Egyed, MD PhD, Valerio De Stefano, MD, Vincenzo Accurso, MD, Alessandra Iurlo, MD PhD, Anders E.A. Dahm, MD PhD, Regina Garcia-Delgado, MD, Nathan Cantoni, MD, Mike Zuurman, PhD, Michael Zaiac, MD, Erik Houtsma, MSc, Amir Iqbal, PhD, Paola Di Matteo, MD PhD, Alberto Alvarez-Larrán, MD

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-134210

Published: 2020

Journal Articles

Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research)

Rudolf A. Benz, MD, Kornelius Arn, MD, Martin Andres, Thomas Pabst, MD PhD, Urban Novak, Felicitas Hitz, MD, Reinhard Zenhäusern, Yves Chalandon, MD PhD, Ulrich Mey, MD, Sabine Blum, Daniel Rauch, Willy Nettekoven, Nathan Cantoni, MD, Mario Bargetzi, MD, Alix O'Meara, MD, Andreas Lohri, MD, Simona Berardi, PhD BSc, Qiyu Li, Georg Stussi, MD

Blood (2018) 132 (Supplement 1): 2875.

https://doi.org/10.1182/blood-2018-99-114301

Published: 2018

Journal Articles

Effects of the Sympathicomimetic Agonist Mirabegron on Disease Course, Mutant Allele Burden, Marrow Fibrosis, and Nestin Positive Stem Cell Niche in Patients with JAK2 -Mutated Myeloproliferative Neoplasms. a Prospective Multicenter Phase II Trial SAKK 33/14

Beatrice Drexler, MD, Jakob Passweg, MD, Martin Bigler, Alexandre PA Theocharides, MD, Nathan Cantoni, MD, Peter Keller, MD, Georg Stuessi, MD, Axel Rüfer, MD, Rudolf A. Benz, MD, Geneviève Favre, MD, Alexandar Tzankov, MD, Pontus Lundberg, PhD, Andrea Fuhrer, PhD, Christine Biaggi, Markus G Manz, MD, Mario Bargetzi, MD, Simon Mendez-Ferrer, PhD, Radek C. Skoda, MD

Blood (2016) 128 (22): 3108.

https://doi.org/10.1182/blood.V128.22.3108.3108

Published: 2016

Journal Articles

Trends of Classification, Incidence, Mortality, and Survival of MDS Patients in Switzerland Between 2001 and 2012

Nicolas Bonadies, MD, Anita Feller, Alicia Rovo, MD, Axel Ruefer, MD, Sabine Blum, MD, Bernhard Gerber, MD, Georg Stuessi, MD, Rudolf A. Benz, MD, Nathan Cantoni, MD, Andreas Holbro, MD, Schmidt Adrian, MD, Thomas Lehmann, MD, Matthias Wilk, MD, Volker Arndt, MD MPH

Blood (2016) 128 (22): 5539.

https://doi.org/10.1182/blood.V128.22.5539.5539

Published: 2016

Journal Articles

The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)

Christoph Driessen, MD PhD, Rouven Müller, MD, Urban Novak, MD, Nathan Cantoni, MD, Daniel Betticher, Nicolas Mach, Michael Gregor, Panagiotis Samaras, MD, Catherine Berset, Stephanie Rondeau, Hanne Hawle, MD, Felicitas Hitz, MD, Thomas Pabst, MD PhD, Thilo Zander, MD

Blood (2016) 128 (22): 487.

https://doi.org/10.1182/blood.V128.22.487.487

Published: 2016

Journal Articles

An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

Giovanni Barosi, MD, Mohan Agarwal, MD, MNAMS, Sonja Zweegman, MD, PhD, Wolfgang Willenbacher, MD, Sima Pakstyte, MD, Reinier Raymakers, MD, PhD, Nathan Cantoni, MD, Ankur Modi, Mahmudul Khan, PhD, Jose Ricardo Perez, MD, Hans Hasselbalch, MD, Jose Pablo Vargas Viveros, MD, Camila C.G. Linardi, MD, PhD, Heinz Gisslinger, MD, Adelmo Henrique Daumas Gabriel, MD, Francesca Palandri, David Lavie, MD, Claire N Harrison, DM FRCP FRCPath

Blood (2012) 120 (21): 2844.

https://doi.org/10.1182/blood.V120.21.2844.2844

Published: 2012

Journal Articles

Large Granular Lymphocyte Expansion Following Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with the Presence of CMV Reactivation and Probably with Acute GvHD and Shows An Indolent Outcome.

Sabine Nann, MD, Alexander Tzankov, MD, Nathan Cantoni, MD, Jörg Halter, MD, Dominik Heim, MD, Dimitrios Tsakiris, MD, Caroline Arber, MD, Andreas Buser, MD, Alois Gratwohl, MD, Andre Tichelli, MD, Alicia Rovo, MD

Blood (2010) 116 (21): 3461.

https://doi.org/10.1182/blood.V116.21.3461.3461

Published: 2010

NARROW

An International Multicentric Observational Study on the Use of Ruxolitinib in Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea: Results from Interim Analysis

Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research)

Effects of the Sympathicomimetic Agonist Mirabegron on Disease Course, Mutant Allele Burden, Marrow Fibrosis, and Nestin Positive Stem Cell Niche in Patients with JAK2 -Mutated Myeloproliferative Neoplasms. a Prospective Multicenter Phase II Trial SAKK 33/14

Trends of Classification, Incidence, Mortality, and Survival of MDS Patients in Switzerland Between 2001 and 2012

The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)

An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

Large Granular Lymphocyte Expansion Following Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with the Presence of CMV Reactivation and Probably with Acute GvHD and Shows An Indolent Outcome.

Email alerts

ASH Publications

American Society of Hematology

An International Multicentric Observational Study on the Use of Ruxolitinib in Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea: Results from Interim Analysis

Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research)

Effects of the Sympathicomimetic Agonist Mirabegron on Disease Course, Mutant Allele Burden, Marrow Fibrosis, and Nestin Positive Stem Cell Niche in Patients with JAK2 -Mutated Myeloproliferative Neoplasms. a Prospective Multicenter Phase II Trial SAKK 33/14

Trends of Classification, Incidence, Mortality, and Survival of MDS Patients in Switzerland Between 2001 and 2012

The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)

An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

Large Granular Lymphocyte Expansion Following Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with the Presence of CMV Reactivation and Probably with Acute GvHD and Shows An Indolent Outcome.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only